Calendario›REGN›Ubamatamab

Ubamatamab

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ensayo de REGENERON PHARMACEUTICALS, INC. en Cancer de ovario · Cancer de trompa de Falopio · Carcinoma peritoneal primario.

Más ensayos de: Cáncer de ovario · Cáncer de trompa de Falopio · Carcinoma peritoneal primario.

Fase

Fase 2

Estado

Reclutando pacientes

Participantes

297

previstos

Centros

56

Fin del objetivo primario

jun 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en may 2025.

Qué mide

Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment (del registro, en inglés) (hasta 3 años)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06787612), actualizada en sep 2026.